07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

AC5 Surgical Hemostatic Device: Clinical trial data

Top-line data from a single-blind, Irish clinical trial in 46 patients with bleeding wounds due to >=2 skin lesion excisions showed that topical AC5 administered by the AC5 Surgical Hemostatic Device met the primary endpoint...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Adenylate cyclase 5 (AC5)

Cardiovascular disease INDICATION: Ischemia / reperfusion injury Mouse and pig studies suggest inhibiting AC5 could help treat ischemia/reperfusion injury. In a mouse model of coronary artery occlusion, heart-specific knockout of AC5 decreased infarct size compared...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Arch Therapeutics deal

Arch Therapeutics (formerly Almah Inc.) reverse-merged with Arch Biosurgery Inc., with Arch Therapeutics remaining as the surviving entity. The company's AC5 is in preclinical development to achieve hemostasis in minimally invasive and open surgical procedures....